Designed as a close research collaboration, the ‘Sanofi-Aventis Regenerative Medicine Program’ at the Salk Institute will support the institute’s stem cell facility, for up to five years, and provide flexible financial support to individual scientists to accelerate innovative research projects in public health, the company said.
Further, it will complement the Salk Institute’s efforts to promote scientific discoveries that have an important impact on the understanding of human health.
Marc Cluzel, senior vice president of R&D at Sanofi-Aventis, said: “This strategic alliance will significantly enrich our research activities in the field of regenerative medicine and will give us the opportunities to apply the discoveries to potential new diagnostics or therapies for human diseases.”